DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Toth Financial Advisory Corp

Toth Financial Advisory Corp trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 37.2% during the fourth quarter, Holdings Channel reports. The firm owned 405 shares of the medical device company’s stock after selling 240 shares during the quarter. Toth Financial Advisory Corp’s holdings in DexCom were worth $31,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Linden Thomas Advisory Services LLC grew its position in shares of DexCom by 2.2% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 21,772 shares of the medical device company’s stock valued at $1,693,000 after buying an additional 473 shares during the last quarter. Dynamic Advisor Solutions LLC grew its holdings in shares of DexCom by 26.8% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 3,902 shares of the medical device company’s stock valued at $303,000 after purchasing an additional 825 shares during the last quarter. Fifth Third Bancorp raised its position in shares of DexCom by 21.5% during the 4th quarter. Fifth Third Bancorp now owns 31,347 shares of the medical device company’s stock worth $2,438,000 after purchasing an additional 5,553 shares during the period. Gradient Investments LLC lifted its holdings in shares of DexCom by 30.1% in the 4th quarter. Gradient Investments LLC now owns 254,543 shares of the medical device company’s stock worth $19,796,000 after purchasing an additional 58,947 shares during the last quarter. Finally, CX Institutional boosted its position in DexCom by 646.3% during the 4th quarter. CX Institutional now owns 3,903 shares of the medical device company’s stock valued at $304,000 after purchasing an additional 3,380 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of several analyst reports. Citigroup increased their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Oppenheimer decreased their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

DexCom Price Performance

NASDAQ:DXCM opened at $88.75 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market cap of $34.67 billion, a P/E ratio of 53.14, a PEG ratio of 2.23 and a beta of 1.12. The business’s 50-day moving average price is $79.50 and its 200 day moving average price is $77.35.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.